Grünenthal has announced the acquisition of US-based Valinor Pharma, LLC (“Valinor”) and its product Movantik® (naloxegol), with a total deal value of approx. $250 million inclusive of all royalty obligations. Grünenthal will finance the transaction using available liquidity. Movantik® is indicated for the oral treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The transaction further expands Grünenthal’s portfolio of established medicines and adds to the company’s growing U.S. business. Gross sales from Movantik® in the United States reached over $200 million in 2023.
Read the full article: Grünenthal Acquires US Company Valinor Pharma //
Source: https://www.prnewswire.com/news-releases/grunenthal-acquires-us-company-valinor-pharma-and-becomes-global-owner-of-movantik-302202574.html